What is Citizens Jmp’s Forecast for NRC Q3 Earnings?

National Research Corporation (NASDAQ:NRC) – Analysts at Citizens Jmp issued their Q3 2026 earnings per share estimates for shares of National Research in a research note issued to investors on Tuesday, September 29th. Citizens Jmp analyst C. Davides anticipates that the company will post earnings of $0.21 per share for the quarter. Citizens Jmp currently has a “Market Outperform” rating and a $26.00 target price on the stock. The consensus estimate for National Research’s current full-year earnings is $0.98 per share. Citizens Jmp also issued estimates for National Research’s Q4 2026 earnings at $0.25 EPS, FY2026 earnings at $0.98 EPS and FY2027 earnings at $1.05 EPS.

National Research (NASDAQ:NRC) last posted its quarterly earnings results on Tuesday, July 28th. The company reported $0.31 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.46. National Research had a return on equity of 164.26% and a net margin of 4.18%.The business had revenue of $35.39 million for the quarter, compared to analysts’ expectations of $34.90 million.

NRC has been the subject of a number of other research reports. Zacks Research upgraded shares of National Research to a “hold” rating in a research note on Monday. Weiss Ratings upgraded shares of National Research from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Friday, August 21st. Finally, Wall Street Zen cut shares of National Research from a “buy” rating to a “hold” rating in a report on Saturday, August 15th. One analyst has rated the stock with a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $26.00.

National Research Price Performance

NASDAQ:NRC opened at $20.19 on Tuesday. National Research has a one year low of $11.01 and a one year high of $23.68. The company has a market cap of $459.32 million, a P/E ratio of 80.76 and a beta of 0.25. The firm’s fifty day moving average price is $20.99 and its two-hundred day moving average price is $19.81. The company has a debt-to-equity ratio of 13.13, a current ratio of 0.65 and a quick ratio of 0.65.

National Research Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 9th. Shareholders of record on Friday, September 25th will be issued a $0.16 dividend. This represents a $0.64 dividend on an annualized basis and a yield of 3.2%. The ex-dividend date of this dividend is Friday, September 25th. National Research’s dividend payout ratio is currently 256.00%.

Institutional Investors Weigh In On National Research

Hedge funds and other institutional investors have recently modified their holdings of the company. Bank of New York Mellon Corp boosted its position in shares of National Research by 4.0% in the first quarter. Bank of New York Mellon Corp now owns 250,707 shares of the company’s stock valued at $4,257,000 after acquiring an additional 9,730 shares during the period. Heartland Advisors Inc. increased its position in National Research by 374.3% during the first quarter. Heartland Advisors Inc. now owns 237,147 shares of the company’s stock worth $4,027,000 after acquiring an additional 187,147 shares during the period. Bank of America Corp DE raised its stake in National Research by 3.0% in the 1st quarter. Bank of America Corp DE now owns 112,468 shares of the company’s stock worth $1,910,000 after purchasing an additional 3,323 shares in the last quarter. Fifth Third Bancorp acquired a new stake in National Research in the 1st quarter worth about $1,531,000. Finally, Quantinno Capital Management LP boosted its holdings in National Research by 61.3% in the 1st quarter. Quantinno Capital Management LP now owns 62,329 shares of the company’s stock valued at $1,058,000 after purchasing an additional 23,682 shares during the period. Institutional investors and hedge funds own 47.26% of the company’s stock.

About National Research

National Research Corporation, formerly traded on the Nasdaq under the symbol NRC and known as NRC Health, provides market research, analytics and performance-improvement services to healthcare organizations. Its solutions are designed to help hospitals, health systems and other providers understand the experiences and expectations of patients, employees, physicians and communities.

The company’s offerings have included patient-experience measurement, employee and physician engagement surveys, reputation and brand research, community health assessments, data analytics and advisory services.